Status:
COMPLETED
Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected People in Wenxi County, Shanxi Province, China
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the safety, effectiveness, and tolerability of the anti-HIV drugs efavirenz and lamivudine/zidovudine given to treatment-naive HIV infected people in Wenxi Co...
Detailed Description
HIV infection in China has reached epidemic proportions, especially in poor rural communities. Among the infected are former commercial plasma donors who became infected through contaminated blood col...
Eligibility Criteria
Inclusion
- HIV infected
- Antiretroviral naive
- CD4 count of less than 350 cells/mm3 within 30 days of study entry
- Willing to use acceptable forms of contraception
- Willing to stay in the study area for the duration of the study
- Willing to not consume traditional Chinese medicines for the duration of the study
- Willing to adhere to the follow-up study schedule
Exclusion
- Presence of an acute serious medical illness within 14 days prior to study entry. Participants with recently diagnosed opportunistic infections (except tuberculosis \[TB\]) and are stable on therapy for more than 30 days are eligible.
- Current pancreatitis
- Require certain medications
- Pregnant or breastfeeding
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2007
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00100594
Start Date
May 1 2005
End Date
May 1 2007
Last Update
February 23 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.